MTEX vs. CLLS, CLYM, IZTC, OCX, ADAG, CRVO, CRBP, TCRX, IMAB, and JMAC
Should you be buying Mannatech stock or one of its competitors? The main competitors of Mannatech include Cellectis (CLLS), Climb Bio (CLYM), Invizyne Technologies (IZTC), OncoCyte (OCX), Adagene (ADAG), CervoMed (CRVO), Corbus Pharmaceuticals (CRBP), TScan Therapeutics (TCRX), I-Mab (IMAB), and Maxpro Capital Acquisition (JMAC). These companies are all part of the "pharmaceutical products" industry.
Mannatech vs.
Cellectis (NASDAQ:CLLS) and Mannatech (NASDAQ:MTEX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, community ranking, media sentiment, valuation and institutional ownership.
63.9% of Cellectis shares are held by institutional investors. Comparatively, 13.0% of Mannatech shares are held by institutional investors. 16.4% of Cellectis shares are held by company insiders. Comparatively, 41.5% of Mannatech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Cellectis received 85 more outperform votes than Mannatech when rated by MarketBeat users. However, 77.65% of users gave Mannatech an outperform vote while only 65.05% of users gave Cellectis an outperform vote.
Cellectis has a beta of 3.11, suggesting that its stock price is 211% more volatile than the S&P 500. Comparatively, Mannatech has a beta of 1.06, suggesting that its stock price is 6% more volatile than the S&P 500.
In the previous week, Cellectis had 1 more articles in the media than Mannatech. MarketBeat recorded 2 mentions for Cellectis and 1 mentions for Mannatech. Cellectis' average media sentiment score of 0.31 beat Mannatech's score of 0.00 indicating that Cellectis is being referred to more favorably in the media.
Cellectis presently has a consensus target price of $6.67, suggesting a potential upside of 338.60%. Given Cellectis' stronger consensus rating and higher probable upside, equities analysts clearly believe Cellectis is more favorable than Mannatech.
Mannatech has a net margin of -1.26% compared to Cellectis' net margin of -234.39%. Mannatech's return on equity of -15.62% beat Cellectis' return on equity.
Mannatech has higher revenue and earnings than Cellectis. Mannatech is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks.
Summary
Cellectis beats Mannatech on 10 of the 18 factors compared between the two stocks.
Get Mannatech News Delivered to You Automatically
Sign up to receive the latest news and ratings for MTEX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mannatech Competitors List
Related Companies and Tools
This page (NASDAQ:MTEX) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy MTEX Stock Free MTEX Stock Alerts